TEZ may control steroid-refractory CRSwNP by targeting upstream mediators of type 2 inflammation, such as group 2 innate lymphoid cells (ILC2s), the major producers of IL-5 and IL-13, thereby contributing to steroid-resistant inflammation. The gene discussed is IL5; the disease is chronic rhinosinusitis with nasal polyps.